Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pronzato

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Cancer Treatment Reviews|December 24, 2013
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trialsLucia Del Mastro, Marcello Ceppi, Francesca Poggio, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2012
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinibFrancesco Grossi, Erika Rijavec, Maria Giovanna Dal Bello, et al.
BMC Cancer|February 21, 2026
End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer centerMichela De Mattia, Andrea Boutros, Virginia Delucchi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2013
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in ItalyFrancesco Grossi, Carlo Genova, Nidia Diaz Gaitan, et al.
Clinical Breast Cancer|October 28, 2008
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)Valentina Guarneri, Antonio Frassoldati, Paolo Bruzzi, et al.
Journal of the National Cancer Institute|December 8, 2005
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trialMarco Venturini, Lucia Del Mastro, Enrico Aitini, et al.
Critical Reviews in Oncology/Hematology|May 30, 2021
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysisMarco Tagliamento, Elisa Agostinetto, Marco Bruzzone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysisAndrea Boutros, Enrica Teresa Tanda, Elena Croce, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 28, 2008
Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusionsSilvio Roncella, Paola Ferro, Bartolomeo Bacigalupo, et al.
Oncotarget|January 22, 2017
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational studyClaudia Bighin, Beatrice Dozin, Francesca Poggio, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Cancer Treatment Reviews|December 24, 2013
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trialsLucia Del Mastro, Marcello Ceppi, Francesca Poggio, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2012
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinibFrancesco Grossi, Erika Rijavec, Maria Giovanna Dal Bello, et al.
BMC Cancer|February 21, 2026
End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer centerMichela De Mattia, Andrea Boutros, Virginia Delucchi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2013
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in ItalyFrancesco Grossi, Carlo Genova, Nidia Diaz Gaitan, et al.
Clinical Breast Cancer|October 28, 2008
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)Valentina Guarneri, Antonio Frassoldati, Paolo Bruzzi, et al.
Journal of the National Cancer Institute|December 8, 2005
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trialMarco Venturini, Lucia Del Mastro, Enrico Aitini, et al.
Critical Reviews in Oncology/Hematology|May 30, 2021
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysisMarco Tagliamento, Elisa Agostinetto, Marco Bruzzone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysisAndrea Boutros, Enrica Teresa Tanda, Elena Croce, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 28, 2008
Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusionsSilvio Roncella, Paola Ferro, Bartolomeo Bacigalupo, et al.
Oncotarget|January 22, 2017
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational studyClaudia Bighin, Beatrice Dozin, Francesca Poggio, et al.
Pageof 10